Taigen Biotechnology Co. Ltd., of Taipei, Taiwan, submitted an FDA new drug application (NDA) for the intravenous formulation of Taigexyn (nemonoxacin) to the CFDA The application was supported by a pivotal phase III trial comparing intravenous formulations of Taigexyn 500 mg to levofloxacin 500 mg in 518 patients with moderate to severe community-acquired pneumonia.